Schizophrenia.com
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
News
jamesbond
September 30, 2021, 2:48pm
1
3 Likes